CliffBio
small molecule

VEMLIDY

TENOFOVIR ALAFENAMIDE FUMARATE

Loss of exclusivityFebruary 2033latest FDA-listed patent expiry
CompanyGilead Sciences →View the full company profile on CliffBio

Drug detail

Brand nameVEMLIDY
Active ingredientTENOFOVIR ALAFENAMIDE FUMARATE
StrengthEQ 25MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2016
Marketing statusRX

Listed patents

PatentExpiresType
9296769*PEDFebruary 2033—
8754065*PEDFebruary 2033—
8754065August 2032substance, product
9296769August 2032substance, product

Regulatory exclusivity

CodeExpires
NPPMarch 2027

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VEMLIDY patent cliff — loss of exclusivity February 2033 | CliffBio